WAP
ARCT icon

Wealthcare Advisory Partners’s Arcturus Therapeutics ARCT Stock Holding History

Wealthcare Advisory Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-11
Closed – – 1227
2018
Q2 		$0 Hold
11
– – ﹤0.01% 1227
2018
Q1 		$0 Buy
+11
New +$76 ﹤0.01% 1078

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wealthcare Advisory Partners's ARCT Position: Q3 2018 in Review

Wealthcare Advisory Partners sold out of Arcturus Therapeutics (ARCT) in Q3 2018, closing a stake of 11 shares.

Wealthcare Advisory Partners first reported a position in ARCT in Q1 2018 and held it in 2 quarters. The position peaked at $0 in Q2 2018. 22 funds tracked by Wall St. Rank hold ARCT as of Q3 2018.

  • Wealthcare Advisory Partners reported no remaining Arcturus Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 11 Arcturus Therapeutics shares in Q3 2018.
  • Wealthcare Advisory Partners first reported a position in Arcturus Therapeutics in Q1 2018 and held it in 2 quarters.
  • Wealthcare Advisory Partners's Arcturus Therapeutics position peaked at $0 in Q2 2018.
  • 22 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2018.

Based on Wealthcare Advisory Partners's 13F filing for Q3 2018, filed 14 Nov 2018.